A Phase 2 interventional study of MSCs and Placebo in MSA - Multiple System Atrophy and MSA, sponsored by Biocells Medical. Not yet recruiting at 1 site in Poland. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Biocells Medical · Phase 2, Interventional, and Treatment
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.
33 studies on the registry are indexed under Shy-Drager Syndrome; 15 are open to participants now.
This study's planned enrollment of 50 is above the median of 41 across 24 interventional studies indexed under Shy-Drager Syndrome.
Browse Shy-Drager Syndrome studies →Biocells Medical is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
200,000,000 cells per infusion
Drug: MSCs
0.9% saline infusion
Other: Placebo
IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period
Intravenous 0.9% saline infusion, volume- and appearance-matched
Change in Unified Multiple System Atrophy Rating Scale (UMSARS)
Time frame: At week 48 from baseline
Change in Health-Related Quality of Life as Measured by the 36-Item Short Form Health Survey (SF-36)
Change in Health-Related Quality of Life as Measured by the 36-Item Short Form Health Survey (SF-36) Total Score with Range: 0-100 where 0 is the lowest value and 100 is the highest; higher scores indicate better health-related quality of life at Week 48
Time frame: At week 48 from baseline
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biocells Medical